Sign in Subscribe

Archive

A collection of 715 issues

Latest

Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. If you have BRAF

Adding immunotherapy to chemotherapy before surgery in stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Adding immunotherapy to chemotherapy before surgery in stage III colon cancer — Clinical Colorectal Cancer The AZUR-4 trial is a Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in previously untreated T4N0 or stage III mismatch repair proficient/

Virtual multidisciplinary prehabilitation model developed for CRC surgery patients

Skip to content The CRC Digest Virtual multidisciplinary prehabilitation model developed for CRC surgery patients Researchers developed a standardized virtual model of care for preoperative and postoperative rehabilitation to reduce complications and improve recovery and quality of life. (World Journal of Surgical Oncology) This content is informational only and does

Depression and anxiety common in CRC patients, linked to lower quality of life

Skip to content The CRC Digest Depression and anxiety common in CRC patients, linked to lower quality of life A cross-sectional study of 300 colorectal cancer patients found psychological disorders such as depression and anxiety worsen quality of life. (South African Journal of Psychiatry) This content is informational only and

CRC Research Update — July 11, 2026

Today's colorectal cancer research highlights

KRAS, NRAS, and BRAF mutation patterns in Chile

Skip to content The CRC Digest KRAS, NRAS, and BRAF mutation patterns in Chile Real-world data from 999 Chilean patients characterized the frequency and sex-specific distribution of KRAS, NRAS, and BRAF mutations. (Journal of Gastrointestinal Oncology) This content is informational only and does not constitute medical advice. Always consult your

RAS and BRAF status in MSI-H/dMMR metastatic CRC

Skip to content The CRC Digest RAS and BRAF status in MSI-H/dMMR metastatic CRC New guidance on the role of RAS and BRAF mutations in MSI-high and dMMR metastatic colorectal cancer. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

CRC Research Finding

Skip to content The CRC Digest ♥ Oral sulfate tablets match PEG for colonoscopy prep with improved patient experience A randomized trial of adult outpatients found oral sulfate tablets were non-inferior to polyethylene glycol formulations for bowel cleansing, with explicit consideration of patient satisfaction—important since bowel prep is cited as

CRC Research Update — July 10, 2026

Today's colorectal cancer research highlights

National Study Examines Follow-Up Colonoscopy Rates After Positive Stool Tests by Race and Ethnicity

Skip to content The CRC Digest National Study Examines Follow-Up Colonoscopy Rates After Positive Stool Tests by Race and Ethnicity A retrospective cohort study linking national data from 2016 to 2023 evaluated follow-up colonoscopy rates, time to colonoscopy, and compliance predictors after positive FIT, FOBT, or mt-sDNA tests, noting that